









Markets
/
Stocks
/
nasdaq-clrb
/

Cellectar Biosciences Inc

CLRB

5.200USD

-0.290-5.28%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.42MMarket Cap

LossP/E TTM



Cellectar Biosciences Inc

5.200

-0.290-5.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

77 / 175

Overall Ranking

228 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

84.000

Target Price

+1430.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 55.87.

Fairly Valued

The company’s latest PE is -0.28, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 195.80K shares, decreasing 64.42% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 56.34K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.95.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.19, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.19

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.29, which is -12.92% below the recent high of -0.25 and -87.12% above the recent low of -0.55.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 77/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.50, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Cellectar Biosciences Inc is 84.00, with a high of 150.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

84.000

Target Price

+1430.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Cellectar Biosciences Inc

CLRB

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.63, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 5.93 and the support level at 4.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.63

Change

-0.65

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.044

Buy

RSI(14)

55.120

Neutral

STOCH(KDJ)(9,3,3)

62.165

Sell

ATR(14)

0.344

Low Volatility

CCI(14)

122.004

Buy

Williams %R

42.857

Buy

TRIX(12,20)

0.440

Sell

StochRSI(14)

12.863

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.206

Sell

MA10

5.171

Buy

MA20

5.000

Buy

MA50

4.893

Buy

MA100

3.383

Buy

MA200

1.877

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 7.48%, representing a quarter-over-quarter decrease of 33.37%. The largest institutional shareholder is The Vanguard, holding a total of 56.34K shares, representing 1.76% of shares outstanding, with 52.91% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

57.40K

-0.30%

Geode Capital Management, L.L.C.

14.78K

+26.38%

Longcor (Jarrod)

2.77K

+56.47%

HRT Financial LP

1.54K

Caruso (James V)

1.64K

BlackRock Institutional Trust Company, N.A.

7.46K

-0.75%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.97, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.